Concord Healthcare Marks First Full Year of Guangzhou Proton Therapy Center Operations

The latest update is out from Concord Healthcare Group Co., Ltd. Class H ( (HK:2453) ).

Concord Healthcare Group Co., Ltd. announced that the proton therapy center at its subsidiary Guangzhou Concord Cancer Center has been in official operation for one year as of 16 December 2024, with all four treatment rooms now in use and key operational indicators performing well. The center has delivered proton therapy to 550 patients, treating over 80 new patients in a single month, and has attracted patients from 31 provincial-level regions in China and more than 20 countries and regions, across an age range of 1 to 91, including completion of China’s first proton therapy for ocular choroidal malignant melanoma in July 2025. This progress strengthens Concord Healthcare’s footprint in precision oncology and enhances its competitiveness in high-end medical services, as the company continues to invest in international collaboration, advanced clinical capabilities, and process optimization to expand access to high-quality proton therapy for cancer patients.

The most recent analyst rating on (HK:2453) stock is a Sell with a HK$2.00 price target. To see the full list of analyst forecasts on Concord Healthcare Group Co., Ltd. Class H stock, see the HK:2453 Stock Forecast page.

More about Concord Healthcare Group Co., Ltd. Class H

Concord Healthcare Group Co., Ltd. is a PRC-based healthcare services provider focused on high-end medical and precision oncology treatment, notably through advanced proton therapy. Through subsidiaries such as Guangzhou Concord Cancer Center, the group targets cancer patients across China and internationally, positioning itself in the premium segment of the oncology care market.

Average Trading Volume: 578,071

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.39B

See more data about 2453 stock on TipRanks’ Stock Analysis page.